Lowering c-Myc to treat aggressive large B‑cell lymphoma
Targeting c-Myc stability in c-Myc overexpressing large B-cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11321531 on NIH RePORTER |
What this research studies
Many aggressive large B‑cell lymphomas make too much of a cancer protein called c‑Myc, and those patients do worse with current treatments. The team is studying an adaptor protein called TBL1 and using a drug (tegavivint) and genetic approaches to make c‑Myc less stable in lymphoma cells. They will use laboratory models and preclinical experiments to see whether lowering c‑Myc slows tumor growth and makes other therapies work better. The goal is to turn those lab findings into new treatment options for patients whose tumors overexpress c‑Myc.
Who could benefit from this research
Good fit: People with aggressive diffuse large B‑cell lymphoma whose tumors show high c‑Myc expression (including double‑expressor, double‑hit, or triple‑hit cases) would be the likely candidates for future trials.
Not a fit: Patients whose lymphomas do not overproduce c‑Myc or who have different cancer types are unlikely to benefit from this specific approach.
Why it matters
Potential benefit: If successful, this could produce a new targeted treatment that improves outcomes for patients with c‑Myc overexpressing large B‑cell lymphoma.
How similar studies have performed: Preclinical work targeting TBL1 and c‑Myc has shown promise in lab models, but clinical proof in patients is still limited.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Alinari, Lapo — Ohio State University
- Study coordinator: Alinari, Lapo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.